用直接作用抗病毒药物治疗囊性纤维化患者慢性丙型肝炎

Q4 Medicine
J. D. Bosia, María Virginia D´Ascenzo, Silvia Borzi, E. Barán, María Cecilia Calzona
{"title":"用直接作用抗病毒药物治疗囊性纤维化患者慢性丙型肝炎","authors":"J. D. Bosia, María Virginia D´Ascenzo, Silvia Borzi, E. Barán, María Cecilia Calzona","doi":"10.52787/TZDH9217","DOIUrl":null,"url":null,"abstract":"The development of new direct acting antiviral drugs for the treatment of Hepatitis C virus infection, has made it possible to obtain an excellent cure rate and extend the indications for eradication of Hepatitis C virus to previously very difficult populations to treat like cystic fibrosis, in whom treatment with classic regimens based on pegylated Interferon plus ribavirin could favor worsening lung function. We present a case of a 41-year-old man with cystic fibrosis, diagnosed with Hepatitis C virus infection, genotype 1a, non-cirrhotic, treated with direct acting antiviral drugs for twelve weeks, obtaining a sustained viral response, without adverse effects. One year later, being on the waiting list, underwent a bipulmonary transplant.","PeriodicalId":35700,"journal":{"name":"Acta Gastroenterologica Latinoamericana","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-03-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Tratamiento de hepatitis crónica por virus de Hepatitis C con drogas antivirales de acción directa en un paciente con fibrosis quística\",\"authors\":\"J. D. Bosia, María Virginia D´Ascenzo, Silvia Borzi, E. Barán, María Cecilia Calzona\",\"doi\":\"10.52787/TZDH9217\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The development of new direct acting antiviral drugs for the treatment of Hepatitis C virus infection, has made it possible to obtain an excellent cure rate and extend the indications for eradication of Hepatitis C virus to previously very difficult populations to treat like cystic fibrosis, in whom treatment with classic regimens based on pegylated Interferon plus ribavirin could favor worsening lung function. We present a case of a 41-year-old man with cystic fibrosis, diagnosed with Hepatitis C virus infection, genotype 1a, non-cirrhotic, treated with direct acting antiviral drugs for twelve weeks, obtaining a sustained viral response, without adverse effects. One year later, being on the waiting list, underwent a bipulmonary transplant.\",\"PeriodicalId\":35700,\"journal\":{\"name\":\"Acta Gastroenterologica Latinoamericana\",\"volume\":\"1 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-03-22\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Acta Gastroenterologica Latinoamericana\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.52787/TZDH9217\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Acta Gastroenterologica Latinoamericana","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.52787/TZDH9217","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

摘要

用于治疗丙型肝炎病毒感染的新型直接作用抗病毒药物的开发,使得有可能获得良好的治愈率,并将根除丙型肝炎病毒的适应症扩展到以前非常难以治疗的人群,如囊性纤维化,在这些人群中,基于聚乙二醇化干扰素加利巴韦林的经典治疗方案可能会导致肺功能恶化。我们报告一例41岁男性囊性纤维化,诊断为丙型肝炎病毒感染,基因型1a,非肝硬化,接受直接作用抗病毒药物治疗12周,获得持续的病毒反应,无不良反应。一年后,由于在等待名单上,她接受了双肺移植手术。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Tratamiento de hepatitis crónica por virus de Hepatitis C con drogas antivirales de acción directa en un paciente con fibrosis quística
The development of new direct acting antiviral drugs for the treatment of Hepatitis C virus infection, has made it possible to obtain an excellent cure rate and extend the indications for eradication of Hepatitis C virus to previously very difficult populations to treat like cystic fibrosis, in whom treatment with classic regimens based on pegylated Interferon plus ribavirin could favor worsening lung function. We present a case of a 41-year-old man with cystic fibrosis, diagnosed with Hepatitis C virus infection, genotype 1a, non-cirrhotic, treated with direct acting antiviral drugs for twelve weeks, obtaining a sustained viral response, without adverse effects. One year later, being on the waiting list, underwent a bipulmonary transplant.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Acta Gastroenterologica Latinoamericana
Acta Gastroenterologica Latinoamericana Medicine-Gastroenterology
CiteScore
0.20
自引率
0.00%
发文量
47
期刊介绍: Está dedicada a la investigación clínica y básica sobre todos los aspectos del aparato digestivo, incluídos el hígado, el páncreas y la nutrición, en seres humanos adultos y niños, animales de experimentación o sistemas celulares.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信